Abstract: Background. Nanotechnology-based drug delivery approaches may help increase therapeutic efficacy and decrease side effects of chemotherapeutics. We investigated expression levels of folate receptor in squamous cell carcinoma of the head and neck (SCCHN) to evaluate folate receptor as a target for nanotherapy.
Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer worldwide and the most common neoplasm in the upper aerodigestive tract. In the United States, head and neck cancer accounts for 3% to 5% of all cancers. Approximately 40,000 new cases and more than 11,000 deaths are estimated in 2006. 1 Despite advances in conventional therapies, including surgery, radiation, and chemotherapy, the overall survival (OS) rate for SCCHN has not significantly improved in the past 3 decades, and the majority of patients with SCCHN stage III or IV disease will die from their disease. 2, 3 Newer treatment modalities are therefore needed to improve outcomes for this group of patients. The folate receptor is a confirmed tumorassociated antigen that binds folate and folatedrug conjugates with very high affinity and shuttles these bound molecules inside cells via an endocytic mechanism. 4 Expression of folate receptor is significant in different types of human carcinomas including carcinomas of the kidney, ovary, endometrium, lung, breast, bladder, and pancreas, making the development of new folate receptor-targeted therapies, and the need to quantify functional folate receptor levels in different tissue specimens, a topic of interest. 4 Folic acid, unlike antibodies, hormones, or other ligands, is internalized to fulfill essential cellular functions, and hence remains retained in endocytic compartments or is released with its attachments into the cytoplasm rather than being trafficked to lysosomes. 5 It has been known for more than a decade that simple covalent attachment of folic acid (or a pteroate-based ligand) to virtually any macromolecule produces a conjugate that can be internalized into folate receptor-bearing cells in an identical fashion to that of free folic acid. 6 There are potential advantages of receptortargeted drug delivery over the conventional use of systemic therapy in that the receptor-mediated approach can reduce drug exposure to normal tissues and hence reduce potential toxicities, in addition to potentially enhancing drug uptake by malignant cells. Indeed, studies have shown that a significant advantage of folate receptor-mediated delivery is the surprisingly low level of toxicity to normal tissues. Studies of a folate-targeted immunotherapeutic drug currently in phase 1 clinical trials have not shown evidence of toxicity in several animal species, even in some cases at supratherapeutic doses delivered over prolonged times. 7 There has been a wide range of successful applications of folate-drug conjugate delivery, including that of proteins and protein toxins, 6, 8 radiopharmaceutical agents, 9,10 low-molecularweight chemotherapeutic agents, 11, 12 antisense oligonucleotides and ribozymes, 13, 14 liposomes with entrapped drugs, 15, 16 and finally drugloaded nanoparticles. [17] [18] [19] Recent developments in nanotechnology have provided researchers with new tools for detection, imaging, and treatment of human cancer. This technology has enabled the development of nanoscale devices that can be conjugated with several functional molecules simultaneously, such as tumor-specific ligands, antibodies, anticancer drugs, and imaging probes. Since these nanodevices are 100-to 1000-fold smaller than cancer cells, they can easily move in and out of leaky blood vessels and interact with receptors, both on the surface of and inside tumor cells. 20 Therefore, their application as tumor cell-specific delivery vehicles for imaging probes and therapeutics is ideal.
We are currently developing a nanoparticle formulation of paclitaxel conjugated to a tumor targeting folate acid (FA) ligand, with the objective of achieving greater drug delivery, and possibly improved pharmacokinetics, To that end, we have examined whether the folate receptor is a good candidate for tumor-targeted agents in SCCHN, by investigating the folate receptor expression status of SCCHN tissue samples. We retrospectively examined the clinical characteristics of patients with SCCHN treated at the Winship Cancer Institute and the Emory Clinic, and correlated disease-free survival (DFS) and OS with folate receptor expression.
PATIENTS AND METHODS
Archival paraffin-embedded tissue specimens from primary SCCHN cases with (48 cases) and without (47 cases) corresponding lymph node metastases were used for immunohistochemical studies. The clinical characteristics of the patients were retrieved from the files in the Department of Pathology and Laboratory Medicine at Emory University. The histological grading of SCCHN was determined by a pathologist (SM), using hematoxylin-eosin-stained sections according to published criteria. All tissue specimens and appropriate clinical information were obtained under the guidelines and approval of the Institutional Review Board of Emory University School of Medicine, Atlanta, GA.
Immunohistochemistry. Folic acid receptor expression in tissue specimens was determined using a goat anti-human folate receptor polyclonal antibody (sc-16387, 1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, CA). Goat IgG at 1:100 dilution was used as a negative control. Immunohistochemical analysis on formalinfixed, paraffin-embedded human specimens was performed according to a modified procedure. In brief, after deparaffinization with xylene and rehydration with EtOH, endogenous peroxidase activity was blocked by incubating the slides in 3% hydrogen peroxide with methanol for 15 minutes. To retrieve the antigens, the tissue slides were heated in a microwave oven in 100M sodium citrate buffer (pH 6.0) for 10 minutes and then allowed to remain at room temperature for 20 minutes. After being washed in PBS, the slides were incubated with serum blocking solution (2.5% normal horse serum, Vector Laboratories, Burlingame, CA) containing Avidin (Blocking Kit, Vector Laboratories) for 30 minutes to decrease the background signal. Next, the slides were incubated with a 1:100 dilution of anti-folate receptor primary antibody at 4 C overnight, and washed with phosphatebuffered saline (PBS). Then, the slides were incubated with a biotinylated secondary antibody for 20 minutes at room temperature and with biotin-avidin peroxidase conjugate (ABC kit, Vector Laboratories) for 15 minutes at room temperature. The substrate (0.1% 3,3 0 -diaminobenzidine solution, Sigma Chemical Co., St. Louis, MO, in PBS with 0.01% hydrogen peroxide) was then added for 5 minutes. Finally, the slides were counterstained with hematoxylin for 50 seconds (Vector Laboratories) and observed by light microscopy.
Evaluation of Folate Receptor Expression. All tissue sections were evaluated by a single pathologist (SM). Adjacent normal epithelium was also evaluated and graded. The level of folate receptor expression was considered positive when characteristic membrane and cytoplasm immunoreactivity was present. Cases with no staining were scored a 0, cases with weak staining (<25% of cells) were scored þ1, and þ2 when >25% cell staining was noted (Figure 1 ). This scoring system was adopted from a recent publication examining folate receptor expression in archival paraffin-embedded tissue from colorectal cancer. 21 Ten bone marrow aspiration cell blocks were used as a control.
Statistical Analysis. McNemar 22 test was used to compare folate receptor expression (expressed as binary) between the primary and lymph node metastatic groups, and Fisher 23 exact test was used to compare folate receptor expression between the no metastatic group and primary metastatic and no metastatic group and lymph node metastatic group. Kaplan-Meier 24 curves and log-rank tests were used to correlate folate receptor expression with DFS and OS in each group, and stratified log-rank test was used to correlate folate receptor to DFS/OS by tumor group. A p value <.05 was considered statistically significant in all analyses.
RESULTS
Patient Characteristics. A total of 143 specimens were available for analysis from 95 patients with SCCHN. Of these, 47 patients (49%) had nonmetastatic and 48 (51%) had metastatic disease. The median age was 62 years (range, 22-88 years), and the male/female ratio was 3/1. The tumor grades were defined as moderately differentiated in 62 (65%), well differentiated in 17 (18%), and poorly differentiated in 16 (17%) patients (Table 1) .
Clinical Characteristics. The median OS for all patients was 4.8 years. The 3-and 5-year OS rates were 68% and 43%, respectively ( Figure  2 ). The median DFS was not reached, with a 3-and 5-year DFS of 65% and 57%, respectively (see Figure 2) .
Folate Receptor Expression. Folate receptor expression of þ1 or more was detected in 43 (45%) primary tumors and 19 (40%) lymph node metastases. An expression level of þ2 or more was detected in 24 (25%) primary tumors and 11 (23%) lymph node metastases. Both cytoplasmic and membrane staining were noted in the tumor cells. No statistical differences were noted between patients in the þ1 and þ2 expression levels of folate receptor. In our data analysis that correlated expression with clinical parameters, the expressers were separated from the nonexpressers, and the analysis compared these 2 groups only. There was a correlation between positive folate receptor expression in primary tumors of the metastatic group and the corresponding lymph node metastasis (p ¼ .0002). Positive folate receptor expression was also correlated with DFS in the nonmetastatic group (p ¼ .0048) and the metastatic group (p ¼ .0127). Furthermore, a correlation was noted between positive folate receptor expression in lymph node metastases and OS (low expression associated with longer survival, p < .0001), as well as DFS (high expression associated with earlier recurrence, p < .001). No correlation was found between folate receptor expression in primary tumors of the nonmetastatic and metastatic groups (p ¼ .563). No correlation existed between folate receptor expression in primary tumors of nonmetastatic group and lymph node metastases of the metastatic group (p ¼ .81). Adjacent normal epithelium was present in 23 of 48 primary tumors in the metastatic group, and only 2 cases showed folate receptor expression. The staining was focal, weak, and confined to the parakeratin and spinous layer. In the nonmetastatic group, 28 of 47 cases had adjacent normal epithelium to examine, with 4 cases exhibiting þ1 staining similar to that described for the metastatic group. No expression was noted in the normal tissues of the mucosa. None of the 10 bone marrows examined from patients without cancer expressed folate receptor. 
DISCUSSION
Our findings demonstrate that folate receptor is expressed in a significant proportion of SCCHN tissues, both in primary tumors and the corresponding lymph node metastases, and appears to be correlated with clinical outcome. Folate receptor expression was an important clinical predictor whether a few (þ1) or a majority (þ2) of tumor cells had positive folate receptor expression. Folate receptor expression appears to be retained in metastatic lymph nodes, suggesting a strong potential for folate receptor as a target for drug delivery in both primary and metastatic SCCHN. Our data suggest a correlation between folate receptor expression and earlier recurrence, indicating that folate receptor expression may be a marker for a more aggressive tumor phenotype. Negative folate receptor expression in our study was associated with longer survival. This further justifies the use of folate receptor-targeted therapies in a subset of SCCHN that seems to exhibit a more aggressive behavior. It is unclear why the OS difference was seen only with the group that had lymph node metastases. Obviously, other clinical factors that were not controlled for may have affected the OS in the nonmetastatic group and made it such that the difference between the groups with detectable versus undetectable folate receptor expression translated only into a DFS, and not an OS difference. This could also indicate that folate receptor expression may have a more significant prognostic importance once the disease is metastatic to regional lymph nodes, which may be an interesting subject for reexamination in other studies.
Considering the potential toxicity to hematopoietic cells that may result from delivery of cytotoxic agents through the folate receptor, bone marrows from 10 patients without cancer were examined for folate receptor expression. None of the marrow specimens expressed folate receptor.
Understanding the biological principles that determine the presence and level of folate receptor expression in SCCHN and other malignancies could open the door for a better understanding of carcinogenesis and tumor progression. It is still unknown whether high expression of folate receptor is responsible for initiation of the carcinogenic process or if malignancy is a precondition for elevated expression of folate receptor. Positive folate receptor was associated with a worse clinical outcome in our study, and its known association with tumor stage and grade in other studies 25 raises questions regarding its role in tumor progression. Because folate receptor is expressed and accessible in multiple malignancies and seems to be expressed selectively in pathologic cells, its targeting allows the delivery of nonspecific drugs selectively into these cells, while normal tissues that lack folate receptor are spared the toxicity of these drugs. Also, unlike other targeted therapies such as cetuximab or herceptin that target markers linked specifically to a known disease, the targeting of folate receptor allows delivery of nonspecific drugs selectively into pathologic cells. What may add to the complexity of the picture however, is the heterogeneity of the folate receptor as documented by studies confirming the existence of 3 distinct mutations of the folate receptor in a squamous cell carcinoma cell line affecting the functional status of the receptor. 26 The observation that folate receptor levels are high in malignant tumors of epithelial origin compared to normal cells, and are associated with tumor stage and grade, raises the question of its role in tumor etiology and progression. 27 Folate receptor mutations may reflect increased folate demands by tumors that offer a growth advantage; this has not been studied in SCCHN and deserves closer examination, as it may affect any therapeutic applications using the folate receptor as a target.
The recent interest in folate ternary nanoparticles conjugated to chemotherapeutic drugs, such as taxanes, has produced both in vitro and in vivo data that demonstrate many advantages over the unconjugated taxane counterpart. These advantages include tumor-specific targeting, decreased side effects in normal cells, improved solubility and bioavailability, retained activity against multidrug resistance, better antiangiogenic activity, and improved therapeutic index (unpublished data from S. Nie and L. Yang). In this study, we have demonstrated the expression of folate receptor in a substantial proportion of primary SCCHN tumors and the associated lymph node metastases, and correlated folate receptor expression levels with clinical outcome. Although only 45% of tumors expressed folate receptor in our study, this is still a very significant population that could potentially benefit from this technology, especially when compared with other targeted therapies that have become standard of care, such as herceptin for breast cancer. Together, these findings open the door for the further development of folate receptor-mediated nanotherapeutic drug delivery in SCCHN. Indeed, we plan to develop similar molecules using heparin or polyglutamic acid as the carrier and FA as the targeting ligand. These targeted nanotherapeutic agents have the potential advantages of reducing drug exposure to normal tissues, hence minimizing toxicities and enhancing drug uptake by tumor cells.
